Causal prophylactic efficacy of atovaquone-proguanil (MalaroneTM) in a human challenge model

Arnold, 1955, The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria (Panama P-F-6 strain), Journal of Laboratory and Clinical Medicine, 46, 391 Basco, 1995, In vitro activity of atovaquone against the African isolates and clones of Plasmodium falciparum, American Journal of Tropical Medicine and Hygiene, 53, 388, 10.4269/ajtmh.1995.53.388 Beerahee, 1999, Clinical pharmacology of atovaquone and proguanil hydrochloride, Journal of Travel Medicine, 6, S13 Brueckner, 1998, Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial, Antimicrobial Agents and Chemotherapy, 42, 1293, 10.1128/AAC.42.5.1293 Canfield, 1995, Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro, Experimental Parasitology, 80, 373, 10.1006/expr.1995.1049 Chulay, 1998, Challenges in the development of antimalarial drugs with causal prophylactic activity, Transactions of the Royal Society of Tropical Medicine and Hygiene, 92, 577, 10.1016/S0035-9203(98)90772-6 Chulay, 1986, Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum, American Journal of Tropical Medicine and Hygiene, 35, 66, 10.4269/ajtmh.1986.35.66 Davies, 1989, The causal prophylactic activity of the novel hydroxynaphthoquinone 566C80 against Plasmodium berghei infections in rats, Acta Leidensia, 58, 115 DeAngelis, 1994, High-performance liquid chromatographic assay for the measurement of atovaquone in plasma, Journal of Chromatography, 652, 211, 10.1016/0378-4347(93)E0387-6 Diem, 1962, 85 Eriksson, 1991, Activity of dihydrofolate reductase inhibitors on the hepatic stages of Plasmodium yoeliiyoelii in vitro, Transactions of the Royal Society of Tropical Medicine and Hygiene, 85, 725, 10.1016/0035-9203(91)90429-3 Fairley, 1946, Researches on paludrine (M.4888) in malaria. An experimental investigation undertaken by the L.H.Q. Medical Research Unit (A.I.F.), Cairns, Australia, Transactions of the Royal Society of Tropical Medicine and Hygiene, 40, 105, 10.1016/0035-9203(46)90052-1 Fisher, 1970, Malaria in soldiers returning from Vietnam, American Journal of Tropical Medicine and Hygiene, 19, 27, 10.4269/ajtmh.1970.19.27 Fleiss, 1981, 44 Fry, 1992, Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80), Biochemical Pharmacology, 43, 1545, 10.1016/0006-2952(92)90213-3 Harinasuta, 1985, Trials of mefloquine in vivax and of mefloquine plus ‘Fansidar’ in falciparum malaria, Lancet, i, 885, 10.1016/S0140-6736(85)91670-8 Høgh, 2000, Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune travellers: a randomised, double-blind study, Lancet, 356, 1888, 10.1016/S0140-6736(00)03260-8 Hussein, 1996, Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone, British Journal of Clinical Pharmacology, 42, 589, 10.1111/j.1365-2125.1996.tb00114.x Lell, 1998, Randomized placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children, Lancet, 351, 709, 10.1016/S0140-6736(97)09222-2 Lell, 2000, Malaria chemoprophylaxis with tafenoquine: a randomized study, Lancet, 355, 2041, 10.1016/S0140-6736(00)02352-7 Looareesuwan, 1996, Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand, American Journal of Tropical Medicine and Hygiene, 54, 62, 10.4269/ajtmh.1996.54.62 Looareesuwan, 1999, Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand, American Journal of Tropical Medicine and Hygiene, 60, 526, 10.4269/ajtmh.1999.60.526 Looareesuwan, 1999, MalaroneTM (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria, American Journal of Tropical Medicine and Hygiene, 60, 533, 10.4269/ajtmh.1999.60.533 Murphy, 1989, Evidence for a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum in humans and confirmation that immunization with a synthetic peptide representative of a region of the circumsporozoite protein retards infection, Journal of Clinical Microbiology, 27, 1434, 10.1128/JCM.27.7.1434-1437.1989 Radloff, 1996, Atovaquone and proguanil for Plasmodium falciparum malaria, Lancet, 347, 1511, 10.1016/S0140-6736(96)90671-6 Shanks, 1998, Efficacy and safety of atovaquone/proguanil for suppressive prophylaxis against Plasmodium falciparum malaria, Clinical Infectious Diseases, 27, 494, 10.1086/514710 Shanks, 1999, Atovaquone and proguanil hydrochloride for prophylaxis of malaria, Journal of Travel Medicine, 6, S21 Shapiro, 1999, Prophylactic activity of atovaquone against Plasmodium falciparum in humans, American Journal of Tropical Medicine and Hygiene, 60, 831, 10.4269/ajtmh.1999.60.831 Shmuklarsky, 1994, Failure of doxycycline as a causal prophylactic agent against Plasmodium falciparum malaria in healthy nonimmune volunteers, Annals of Internal Medicine, 120, 294, 10.7326/0003-4819-120-4-199402150-00006 Shortt, 1951, The pre-erythrocytic stage of Plasmodium falciparum, Transactions of the Royal Society of Tropical Medicine and Hygiene, 44, 405, 10.1016/S0035-9203(51)80019-1 Snounou, 1993, Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections, Molecular and Biochemical Parasitology, 58, 283, 10.1016/0166-6851(93)90050-8 Sukwa, 1999, A randomized, double-blind, placebocontrolled field trial to determine the efficacy and safety of MalaroneTM (atovaquone/proguanil) for the prophylaxis of malaria in Zambia, American Journal of Tropical Medicine and Hygiene, 60, 521, 10.4269/ajtmh.1999.60.521 WHO, 2000, 67